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1. Introduction 
Acute myeloid leukemia (AML) is a serious and often lethal disease. Over the last several 
decades, although there have been advances in the treatment of AML, however, the survival 
of patients with AML has not changed significantly1-3. Most of patients will relapse within 
two years and ultimately died of the disease4. The scarce efficacy of current treatments 
indicates the resistance of leukemia cells to cytotoxic agents and even immunotherapy and 
survival from the treatment without major injure. Thus, there is a desperate need for new 
effective therapies for AML patients. 
The hematopoietic system is thought to originate from pluripotent hematopoietic stem cells 
(HSC) capable of producing a hierarchy of downstream multilineage and unilineage 
progenitor cells that differentiate into mature cells5. HSCs have self-renewal and can 
differentiate into multiple lineages6. HSC self-renewal is either symmetrical, producing two 
daughter HSCs, or asymmetrical, producing an identical HSC and a progenitor with 
diminished self-renewal capacity but with the ability to enact clonal expansion7. It is also 
believed that leukemia is initiated and maintained by a rare population of leukemia cells 
with stem cell properties similar to those of normal HSCs known as leukemic stem cell 
(LSC). The concept that a rare population of the tissue stem cell maybe the cellular origin of 
cancer was proposed almost 150 years ago. Approximately 50 years ago the concept that 
only a small subpopulation of so-called LSCs may be connected to the maintenance and 
evolution of myeloid leukemia emerged. Conclusive evidences for the existence of LSCs 
come from the function assay using SCID-leukemia and NOD/SCID-leukemia 
xenotransplantation models in which mice were transplanted with leukemic cells from the 
bone marrow and peripheral blood of AML patients. These studies demonstrated that the 
leukemic grafts were highly representative of the original patients disease and the 
SCID/leukemia initiating cell presented at a frequency of 0.2-100/106 mononuclear cells8. 
More recently, this principle has also been extended to other tumors, such as breast, brain, 
prostate, pancreas, colon, lung, liver, and head and neck tumors9-15. Due to a high degree of 
phenotypic and functional similarity, it has been hypothesized that most human leukemias 
arise from transformation of HSCs. However, other studies have shown that transduction of 
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the MLL-ENL or MOZ-TIF2 fusion genes into HSCs, common myeloid progenitors, and 
granulocyte-macrophage progenitors resulted in the identical leukemia. These results 
indicate that committed progenitors may acquire self-renewal capability and transform into 
LSCs16,17.  
LSCs have been reported to be the only tumorigenic population and play a central role in 
relapse because of the failure of current chemotherapy to eradicate them. The existence of 
LSC highlights the critical need for the new therapeutic strategies to directly target the LSC 
population for ultimately curing leukemia. 
Basing on the solid evidences that leukemia is stem cell disease, the view of drug resistance 
changes. It is believed that LSCs are naturally resistant to conventional chemotherapy and 
serve as the main mediators of drug resistance18-22. Moreover, it is accepted that drug 
resistance is governed by the mutations that confer protection mechanism through 
modulation of cell survival factors. To that end, a number of signal pathways involved in 
LSCs viability and survival, namely the Hedgehog, Ras, FLT3, PI3K/AKT, NF-κB, mTOR 
are aberrantly regulated in LSCs. Because of their wide-ranging biological effects, 
deregulation one or more of these pathways may give rise to a failure of current 
chemotherapy. Others and we have long been interested in exploring the mechanisms of 
drug resistance of LSCs influenced by these cell survival pathways and molecular 
interaction networks. Thus we can determine the critical elements and the general rules 
driving the network to guide the use of specific inhibitors of a given pathway. This review 
will focus on the drug resistance of LSCs and the signal pathway and their potential cross-
talk. (Figure1). 
2. Leukemic stem cells and drug resistance 
According to the hierarchy model, Leukemia consists of a heterogeneous population, within 
which only a rare population of LSCs sustains the disease. LSCs share some properties of 
normal stem cells, Such as self-renewal potential, proliferation and essential property of self-
protection. The whole drug resistance concept has been revised incorporating the LSC 
paradigm. LSCs play the key role in the drug resistance of leukemia. LSCs present in the 
original tumour mass and survive chemotherapy, whereas the committed but variably 
differentiated cells are killed. Several mechanisms make LSCs more resistant to conventional 
chemotherapeutic agents. For example, LSCs exhibited higher expression of drug resistance 
proteins, such as lung resistance-related protein (LRP) and multiple resistance-associated 
proteins (MRP)23. Recent work from our group suggests that LSCs are resistance to 
mitoxantrone and daunorubicin via up-regulation of ABCG2 and MRP.  Another group of 
investigators have demonstrated that LSCs isolated from human leukemia are 
predominantly in the G0 phase of the cell cycle that made it resistance to cell cycle specific 
chemotherapeutic agents such as Ara-c24. Furthermore, LSCs have capacity for DNA repair. 
As a result, at least some of LSCs can survive chemotherapy including DNA damage agents 
such as alkylating agents25. Moreover, LSCs are resistant to chemotherapy through impaired 
apoptosis pathway26-28. Our unpublished data show that LSCs up-regulated Bcl2 protein 
and Bcl2 siRNA enhanced the sensitivity of LSCs to mitoxantrone cytotoxicity. The 
properties of LSCs suggest that the current chemotherapy drugs will not be curative. 
Current studies focus on a number of signaling pathways that regulate chemoresistance of 
LSCs through survival pathway. We will outline some of these pathways and their potential 
in drug resistance.  
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Fig. 1. Signal transduction pathways important in leukemic stem cells 
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3. Hedgehog pathway  
‘Hedgehog’ (HH) molecules are secretory signaling proteins that were first discovered in 
Drosophila. Three HH homologs have been identified in humans including Sonic hedgehog 
(SHH), Indian hedgehog (IHH) and Desert hedgehog (DHH). Secreted hedgehog molecules 
bind to and inhibit the cell surface receptor Patched 1 protein on target cells. Smoothened is 
a transmembrane protein primarily located in the membrane endosomes. It is proposed that 
the endogenous agonist of SMO is a small intracellular molecule transported out of the cell 
by PTCH1, a mechanism preventing binding to SMO. Upon binding an HH ligand, PTCH1 
is internalized and inactivated so that the endogenous agonist of SMO accumulates in 
cytoplasm and activates SMO. Activated SMO causing release of the Gli family of transcrip-
tion factors (Gli-1, -2, and -3), which can then translocate into the nucleus and activate gene 
transcription that control the cell cycle, signal transduction, and apoptosis. HH pathway, 
which is one of the main pathways that control stem cell fate, self-renewal and maintenance, 
plays a central role in drug resistance of cancer cells29-33.  
HH pathway makes LSCs more resistance to chemotherapy through several mechanisms. 
First, HH controls the cell cycle fate during cell proliferation. Activation of the HH pathway 
may promote tumor repopulation after chemotherapy and contribute to chemotherapy 
resistance in cancers. Second, HH signaling may act as upstream of other signal pathway 
that regulate self-renewal of stem cell. The loss of HH signaling by genetically disrupting 
Smo resulted in the inhibition leukemic stem cells and prolonged survival. Thus, HH 
pathway activity is required for maintenance of leukemic stem cells and dictates LSC fate 
decisions34,35. It raises the possibility that the drug resistance and disease relapse might be 
avoided by targeting this essential stem cell maintenance pathway. Furthermore, HH 
pathway contributes to the survival of tumor progenitor cells by opposing the activation of 
both intrinsic and extrinsic apoptosis cascades. Gli-1 is considered the positive 
transcriptional transactivator in the Shh pathway. Gli-1 was also able to induce endogenous 
Bcl2 expression. Moreover, Hh signal also up-regulats the expression of Bcl2 through 
activated PI3K and AKT. We have been demonstrated that Bcl2 was high expression via up-
regulation Gli in LSCs. These findings suggest that in addition to regulating proliferation of 
tumor progenitor cells, HH signaling may support the survival of tumor progenitor cells. 
Moreover, HH pathway regulates the expression of two ABC proteins, multidrug resistance 
protein-1 and breast cancer resistance protein and leads to the efflux of various 
chemotherapeutic drugs36. 
4. Ras signaling pathway  
Ras, the protein product of the ras proto-oncogenes, is localized to the inner surface of the 
cell membrane, in which it becomes functional in tranducing the mitogenic signals of 
tyrosine kinase receptors that regulate diverse signaling pathways involved in cell growth, 
differentiation and apoptosis. The family of ras includes N-ras, K-ras, and H-ras. Ras 
mutations are most commonly associated with cancer including leukemia. Transplantation 
of highly purified hematopoietic stem cells (HSCs) and myeloid progenitors identified HSCs 
as the primary target for the oncogenic Kras mutation. Karyotypic analysis further indicated 
that secondary genetic hit(s) target lineage-specific progenitors rather than HSCs for 
terminal tumor transformation into leukemic stem cells. Thus, the cellular mechanism 
underlying oncogenic Kras-induced leukemogenesis, with HSCs as the primary target by 
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the oncogenic Kras mutations and lineage-committed progenitors as the final target for 
cancer stem cell transformation37. Once activated, ras is able to trigger several signaling 
including Raf-Mek-Map kinase pathway38, FMS-like tyrosine kinase 3 (FLT3) pathway39, 
and phosphoinositide 3-kinase (PI3K)/ cytoplasmic protein kinase B (AKT) pathway. The 
potential relevance of the Raf-MEK-MAP kinase pathway to abnormal hematopoiesis is 
highlighted by the ability of a constitutively activated mutant Raf to eliminate growth factor 
dependence of hematopoietic cells. Ras also activates the PI3K pathway, which can result in 
suppression of apoptosis by directly activating AKT. The PI3K/AKT pathway is important 
for relaying survival signals in hematopoietic cells by Ras. Mutations of ras in LSCs result in 
refractory and relapse of leukemia40. 
5. FMS-like tyrosine kinase 3 signaling 
The FLT3 gene, also known as fetal liver tyrosine kinase 2 (PLK2), encodes a membrane-
bound receptor tyrosine kinase (RTK). FLT3 have been shown to play a role in 
leukemogenesis. In most examined patient cohorts, FLT3 is consistently associated with 
unfavorable prognosis and relapse of AML patients. In recent studies, it was also shown that 
FLT3 was expressed in LSCs. FLT3 activates special anti-apoptotic signal by up-regulating 
Bcl2 family. In additionally, FLT3 mediates drug resistance through activating PI3K/AKT 
survival pathway41-43. Interestingly, simultaneous mutations of ras and FLT3 are rare, 
suggesting functional overlap between the two. 
6. The PI3K/AKT cell survival pathway 
Oncogenic ras and FLT3 have been shown to activate PI3Ks in AML. Moreover, activating 
mutations of c-Kit tyrosine kinase receptor, PI3K p110β and/or δ overexpression, low levels 
of PP2A, autocrine/paracrine secretion of growth factors such as IGF-1 and VEGF also 
result in PI3K/Akt signaling up-regulation. PI3Ks are heterodimers with separate 
regulatory (p85) and catalytic (p110) subunits. PI3K activation may be due to the close 
proximity of p110 to its lipid substrates in the membrane and relief of the inhibitory effect of 
p85 on p110 kinase activity upon RTK-p85 interaction. Direct binding of p110 to activating 
ras proteins following growth factor stimulation further stimulates PI3K activity. The 
increasing evidences have supported that PI3K plays critical roles in the chemotherapy-
resistance in LSCs. Furthermore, the downstream effector of PI3K, AKT (a subfamily of the 
serine/threonine protein kinases), have been associated with the cell growth and survival of 
cancer stem cell44-46. Three AKT isoforms (AKT1, AKT2, and AKT3) have been identified, all 
of which share an N-terminal PH domain, with central kinase domain, and a 
serine/threonine-rich C-terminal region. The intermediates of the PI3K/AKT survival 
pathway are activated in LSCs and high level of PI3K/AKT has been linked to poor 
prognosis and chemoresistance. Tumor suppressor gene Phosphatase and tensin homolog 
(PTEN) is negative regulator of AKT pathway. Mutations or losses of PTEN have been 
found in a large number of cancers including brain, breast, prostate and leukemia47,48. Loss 
of PTEN function results in AKT activating and cancer resistance to conventional therapy 
and a relapse following initial regression. Shoman etal have reported a strong correlation 
between down-regulation of PTEN expression and failure to respond to tamoxifen 
treatment in estrogen receptor-positive tumors49. In the hematopoietic system, recently 
studies show that conditional deletion of PTEN result in leukemia47. Thus PI3K/Akt 
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pathway plays the critical role in the LSC resistance to a number of anti-tumor agents. 
PI3K/AKT pathway controls the expression of the membrane ATP binding cassette (ABC) 
transporter, multidrug resistance-associated protein 1 to extrude chemotherapeutic drugs. 
Furthermore, PI3K/AKT activating defect the apoptosis pathway of LSC to protect LSC 
from chemotherapy. 
7. NF-κB signaling pathway 
Nuclear factor of kB (NF-κB) is a family of closely related dimeric transcription factors that 
bind to the kB sites. NF-κB is an inducible and ubiquitously expressed transcription factor 
that regulates cell survival, inflammation, and differentiation. It is becoming increasingly 
clear that NF-κB signaling plays critical roles in cancer development and progression. 
Cancer cells especially poorly differentiated cancer cells show activated NF-κB in the 
nucleus, suggesting that activated NF-κB regulates its downstream genes to promote cancer 
cell growth. The exciting results have shown that NF-κB is constitutively activated in LSCs 
whereas it is strikingly not activated in their normal counterpart, suggesting this 
transcription factor is preferentially in LSCs50. This provides a possible that specific target 
the LSCs while spare the normal HSCs. More importantly, it has been well known that 
many chemotherapeutic agents such as neucleoside analogs and anthracyclines induce the 
activity of NF-κB, which causes drug resistance in cancer cells51. Therefore, targeting NF-κB 
would be promising strategy to overcome the drug resistance of LSCs. 
8. Strategies to overcome drug resistance through regulating survival signal 
pathways of LSCs 
The concept that leukemia is a stem cell disease has the potential to change the view of drug 
resistance. As the understanding of the signaling pathway involved in the survival and 
chemoresistance of LSCs, it is likely to identify new mechanism-based effective therapy 
directed at LSCs to cure leukemia.   
9. Targeting of hedgehog pathway  
As indicated above, The HH pathway is activated in LSCs and plays the central role in drug 
resistance. Cyclopamine is a natural steroidal alkaloid that inhibits the HH pathway by 
directly binding and suppressing the Smo receptor. Recent studies showed that cyclopamine 
inhibits various human malignancies including breast, prostate, liver, pancreas, small cell 
lung cancer, and glioma52,53. Importantly, continuous cyclopamine eliminated PC3 cancer-
initiating cells. Similarly, cyclopamine treatment also counteracts the expansion of multiple 
myeloma (MM) stem cell and decrease the number of MM stem cell54. Furthermore, 
blocking the HH signal pathway by Gli siRNA or humanized anti-SHH antibodies has been 
shown to induce apoptosis in a wide variety of tumors through activation of intrinsic and 
extrinsic apoptosis cascades and resensitized the chemoresistant CSCs. Recently, Kobune  et 
al showed that HH signaling is active in CD34+ leukemic cells. These CD34+ cells express 
the downstream effectors glioma-associated oncogene homolog Gli-1 or Gli-2, indicative of 
active HH signaling. Moreover, inhibition of HH signaling with the naturally derived 
Smoothened antagonist cyclopamine, endogenous HH inhibitor hedgehog-interacting 
protein or anti-hedgehog neutralizing antibody induced apoptosis of these CD34+ cells 
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exhibited resistance to cytarabine (Ara-C). Furthermore, combination with cyclopamine 
significantly reduced drug resistance of CD34+ cells to Ara-C55. Taken together, these 
studies suggest that selective target HH pathway may lead to more effective cancer 
therapies. 
10. Targeting of the ras pathway   
The emerging evidences have shown that increase in ras activity may be an early step in the 
deveplopment of leukemia. The preclinical concept of farnesyltransferase blockade as a 
targeted therapy against oncogenic Ras has clearly evolved with the recognition that many 
proteins involved signaling pathways in tumor cells undergo farnesylation. Several 
farnesyltransferase inhibitors as monotherapy in cancer in vitro or in clinical trial 
demonstrate encouraging responses and good tolerability.  BMS-214662, a cytotoxic 
farnesyltransferase inhibitor, previously reported to selectively kill nonproliferating 
subpopulation in tumor cells. Recent studies have also been shown that BMS-214662, alone 
or in combination with imatinib or dasatinib, effectively induced apoptosis of resistant CML 
stem cells and potently induced apoptosis of both proliferating and quiescent CML 
stem/progenitor cells with less than 1% recovery of Philadelphia-positive long-term culture-
initiating cells. Normal stem/progenitor cells were relatively spared by BMS-21466256. Our 
unpublished data also showed that manumycin enhanced mitoxantrone-induced apoptosis 
in LSCs.  These data suggest that RAS contribute to drug resistance of LSC and are potential 
targets for new therapeutic strategies. Farnesyltransferase inhibitor may offer potential for 
eradication of LSC. 
11. Regulation of the PI3K/AKT pathway  
The increasing evidence has shown that activated FLT3, PI3K/AKT pathway is critical for 
drug resistance of LSCs, therefore, downregulation of FLT3, PI3K, and AKT could sensitize 
LSCs to chemotherapy and overcome drug resistance. The PI3K/ AKT pathway may be 
inhibited with PI3K (LY294002, PX-866), PDK1 (OSU-03012, celecoxib), AKT (A-443654, 
perifosine, tricribine) or downstream mTOR inhibitors such as rapamycin and modified 
rapamycins (CCI-779 andRAD001). Inhibition of the PI3K/AKT pathway by the specific 
pathway inhibitors LY294002 leads to a dose-dependent decrease in survival of LSCs57. 
LY294002 also significantly reduced the survival of SP fraction within MCF7 cells and 
decrease cancer stem-like cells58. Wortmannin are able to inhibit CML and AML cell 
proliferation and to synergize with targeted tyrosine kinase inhibitors. Additionally, dual 
PI3K/PDK-1 Inhibitor BAG956 have been demonstrated effective against leukemia59. 
Recently, publication by Yilmaz and colleagues demonstrated that mammalian target of 
rapamycin (mTOR) inhibition with rapamycin not only depleted leukaemia-initiating cells 
but also restored normal HSC function47. In conclusion, inhibition of this pathway leads to 
an increase in apoptosis in LSCs, and that it potentiates the response to cytotoxic 
chemotherapy. 
12. Targeting of NF-κB Signaling Pathway 
Previous studies have demonstrated that NF-κB, a known regulator of growth and survival, 
is constitutively active in LSCs but not in normal hematopoietic stem cells (HSCs). These 
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suggest that LSC-specific targeted therapy should be feasible using a variety of strategies. 
Guzman etal have previously shown that a combination of the proteasome inhibitor MG-132 
and the anthracycline idarubicin was sufficient to preferentially ablate human LSCs in vitro 
while sparing normal HSCs51. These studies demonstrate that LSC-specific targeting can be 
achieved. Recently, Guzman etal also demonstrated that the single plant-derived compound 
parthenolide (PTL) effectively eradicates AML LSCs by inducing robust apoptosis via 
induce oxidative stress and inhibit NF-κB while sparing normal HSCs60. These properties 
make these compound an attractive agent for clinical evaluation. However, the poor 
solubility of PTL makes pharmacologic use of the compound difficult. Thus, more recently, 
orally bioavailable Dimethylamino- parthenolide (DMAPT) induces rapid death of primary 
human LSCs from both myeloid and lymphoid leukemias, and is also highly cytotoxic to 
bulk leukemic cell populations61. Servida etal also reported that PS-341 induced apoptosis in 
leukemia progenitor cells62. In an effort to expand strategies for selectively targeting LSCs, 
the recent study has been shown that the compound TDZD-8 (4-benzyl,2-methyl,1,2,4-
thiadiazolidine, 3,5 dione), which was originally developed as a non-ATP competitive 
inhibitor of GSK-3β, was strongly and selectively cytotoxic to multiple types of primary 
leukemia cells, as well as phenotypically and functionally defined LSCs. The cytotoxicity is 
associated with a rapid loss of membrane integrity, induction of oxidative stress, and 
inhibition of several signal transduction pathways including NF-κB and FLT363.   
13. Conclusions  
Altogether, these recent investigations have revealed that leukemia originate from leukemic 
stem cells. The leukmic stem cells can provide critical functions in leukemic initiation and 
progression and recurrent disease states. LSCs are often resistant to standard chemotherapy, 
which make leukemia refractory and relapse. The concept of leukemia as a stem cell disease 
has the potential to change significantly the view of the problem of drug resistance. 
Research efforts to discover the specific signal pathway serving to resistance of LSCs should 
lead to more effective and safe leukemia therapeutic treatments for ultimately curing 
leukemia. Future studies will focus on the identifying and targeting of critical signal 
pathway to overcome the drug resistance of LSCs for improvement of the current leukemia 
treatments. 
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